JP2021523170A5 - - Google Patents
Info
- Publication number
- JP2021523170A5 JP2021523170A5 JP2020563542A JP2020563542A JP2021523170A5 JP 2021523170 A5 JP2021523170 A5 JP 2021523170A5 JP 2020563542 A JP2020563542 A JP 2020563542A JP 2020563542 A JP2020563542 A JP 2020563542A JP 2021523170 A5 JP2021523170 A5 JP 2021523170A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- neutralizing agent
- combination according
- nkg2a
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059910A JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671521P | 2018-05-15 | 2018-05-15 | |
| US62/671,521 | 2018-05-15 | ||
| PCT/EP2019/062305 WO2019219658A1 (en) | 2018-05-15 | 2019-05-14 | Treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059910A Division JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523170A JP2021523170A (ja) | 2021-09-02 |
| JP2021523170A5 true JP2021523170A5 (enExample) | 2022-05-26 |
| JP7531404B2 JP7531404B2 (ja) | 2024-08-09 |
Family
ID=66752041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563542A Active JP7531404B2 (ja) | 2018-05-15 | 2019-05-14 | 癌の処置 |
| JP2024059910A Pending JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059910A Pending JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12209126B2 (enExample) |
| EP (1) | EP3793607A1 (enExample) |
| JP (2) | JP7531404B2 (enExample) |
| KR (1) | KR102885515B1 (enExample) |
| CN (1) | CN112203691A (enExample) |
| AU (2) | AU2019270277B9 (enExample) |
| CA (1) | CA3099820A1 (enExample) |
| EA (1) | EA202092696A1 (enExample) |
| IL (1) | IL278618B2 (enExample) |
| MA (1) | MA52627A (enExample) |
| SG (1) | SG11202011117VA (enExample) |
| TW (1) | TW202011989A (enExample) |
| WO (1) | WO2019219658A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| CN113583127A (zh) * | 2020-04-30 | 2021-11-02 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| CN115516086A (zh) * | 2020-05-13 | 2022-12-23 | 南京传奇生物科技有限公司 | 类猿icp47及变体减少同种异体细胞宿主排斥的组合物及方法 |
| WO2023284874A1 (zh) * | 2021-07-16 | 2023-01-19 | 克莱格医学有限公司 | 用于肿瘤免疫学的组合物和方法 |
| PE20241475A1 (es) * | 2021-10-04 | 2024-07-17 | Servier Lab | Terapia del cancer dirigida a nkg2a |
| JP2025500845A (ja) * | 2021-12-14 | 2025-01-15 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| PT1831258E (pt) | 2004-12-28 | 2016-01-07 | Univ Genova | Anticorpos monoclonais contra nkg2a |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| KR20100110864A (ko) | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR102047248B1 (ko) | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| RU2017105425A (ru) * | 2014-08-28 | 2018-09-28 | Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины |
| AU2015316991B2 (en) | 2014-09-16 | 2021-04-01 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
-
2019
- 2019-05-14 EA EA202092696A patent/EA202092696A1/ru unknown
- 2019-05-14 CN CN201980031725.8A patent/CN112203691A/zh active Pending
- 2019-05-14 JP JP2020563542A patent/JP7531404B2/ja active Active
- 2019-05-14 AU AU2019270277A patent/AU2019270277B9/en active Active
- 2019-05-14 IL IL278618A patent/IL278618B2/en unknown
- 2019-05-14 WO PCT/EP2019/062305 patent/WO2019219658A1/en not_active Ceased
- 2019-05-14 TW TW108116510A patent/TW202011989A/zh unknown
- 2019-05-14 SG SG11202011117VA patent/SG11202011117VA/en unknown
- 2019-05-14 MA MA052627A patent/MA52627A/fr unknown
- 2019-05-14 KR KR1020207035232A patent/KR102885515B1/ko active Active
- 2019-05-14 CA CA3099820A patent/CA3099820A1/en active Pending
- 2019-05-14 EP EP19728320.3A patent/EP3793607A1/en active Pending
- 2019-05-14 US US17/054,920 patent/US12209126B2/en active Active
-
2024
- 2024-04-03 JP JP2024059910A patent/JP2024102055A/ja active Pending
-
2025
- 2025-01-14 AU AU2025200275A patent/AU2025200275A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523170A5 (enExample) | ||
| JP2024102055A5 (enExample) | ||
| IL278618B1 (en) | Cancer treatment | |
| JP2018518454A5 (enExample) | ||
| JP2021531254A5 (enExample) | ||
| CN114173815A (zh) | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的联合疗法中的用途 | |
| JP2018501197A5 (enExample) | ||
| JP2022530404A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2018070648A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| US20250032633A1 (en) | Antibody-drug conjugate and application thereof | |
| TW201545758A (zh) | 腫瘤免疫力之調節 | |
| HRP20160082T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| WO2018038684A1 (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| JP2018515137A5 (enExample) | ||
| TW201925230A (zh) | 以抗egfr療法治療癌症的組成物及方法 | |
| JP2023502876A5 (enExample) | ||
| JP2021530428A (ja) | 頭頸部癌の処置 | |
| AU2021378793B2 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| EP3145544B1 (en) | Ang2 antibodies | |
| CN115485298A (zh) | 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合 | |
| US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant |